| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/24/2014 | WO2014060366A1 N-substituted 3,4-bis (catechol) pyrrole compounds, and the preparation and use thereof in the treatment of cancer |
| 04/24/2014 | WO2014060364A1 Sulfestrol for treating cancer |
| 04/24/2014 | WO2014060358A1 Fosfestrol for use in curative or palliative treatment of cancer in female mammals |
| 04/24/2014 | WO2014060357A1 Multifunctional coupling reagents having an azlactone function |
| 04/24/2014 | WO2014060347A1 Fosfestrol for use in curative or palliative treatment of prostate cancer |
| 04/24/2014 | WO2014060341A1 Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists |
| 04/24/2014 | WO2014060328A1 6-aminoindole derivatives as trp channel antagonists |
| 04/24/2014 | WO2014060324A1 Aripiprazole formulations |
| 04/24/2014 | WO2014060150A1 Cosmetic or dermatological preparation for prophylaxis and/or treatment of atopic dermatitis |
| 04/24/2014 | WO2014060138A1 Compositions comprising a silver salt of sucrose octasulfate and a potassium salt of sucrose octasulfate for protection of mucosal epithelia |
| 04/24/2014 | WO2014060113A1 Novel kinase inhibitors |
| 04/24/2014 | WO2014060112A1 Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| 04/24/2014 | WO2014059902A1 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| 04/24/2014 | WO2014059901A1 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| 04/24/2014 | WO2014059884A1 Marker of metabolite of optically-active 2-hydroxyltetrathienopyridine derivative, and preparation method and use thereof |
| 04/24/2014 | WO2014059797A1 Use of ivermectin and derivatives thereof |
| 04/24/2014 | WO2014059740A1 Tetracyclic anthraquinone derivatives |
| 04/24/2014 | WO2014059702A1 Benfotiamine polymorphs, preparation method and use thereof |
| 04/24/2014 | WO2014059649A1 Lycopene microcapsule preparation method |
| 04/24/2014 | WO2014059558A1 Durable analgetic sebacoyl dinalbuphine ester-plga controlled release formulation |
| 04/24/2014 | WO2014059522A1 Compositions comprising s-adenosylmethionine and a gallic acid ester |
| 04/24/2014 | WO2014059512A1 Oral drug delivery formulations |
| 04/24/2014 | WO2014059499A1 Preparation method and composition of a pharmaceutical drug from quenodeoxicholate linked to a natural, d-fructose-analogue, sulfamate-derived monosaccharide (topiramate) and to a phenylketone (bupropion) for the treatment of obesity and plurimetabolic syndromes |
| 04/24/2014 | WO2014059484A1 CANCER THERAPY USING miRNAs |
| 04/24/2014 | WO2014037833A3 Compositions and methods for treatment of inflammation and lipid disorders |
| 04/24/2014 | WO2014036502A3 Tetracycline compounds |
| 04/24/2014 | WO2014033343A9 Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension |
| 04/24/2014 | WO2014031872A3 Small molecule inhibitors for treating parasitic infections |
| 04/24/2014 | WO2014027262A3 Compositions and methods for the treatment angina and cardiovascular conditions |
| 04/24/2014 | WO2014027251A3 Aminopyridine compounds and their uses |
| 04/24/2014 | WO2014020480A3 Compositions and methods for the treatment migraine and neurologic diseases |
| 04/24/2014 | WO2014013465A3 Salts and hydrates of antipsychotics |
| 04/24/2014 | WO2014006529A3 Compositions and methods for the treatment of moderate to severe pain |
| 04/24/2014 | WO2013150545A8 Process for preparation of benzimidazole derivatives and salts thereof |
| 04/24/2014 | WO2013092417A3 Active substance combinations of one or more alkyl ethers of glycerol and one or more physiologically acceptable hydroxamic acids, and cosmetic or dermatological preparations containing such active substance combinations |
| 04/24/2014 | WO2013043304A9 Estrogen receptor ligands and methods of use thereof |
| 04/24/2014 | WO2013038267A8 Tamper resistant pharmaceutical formulations |
| 04/24/2014 | WO2013033249A3 Neutron irradiation therapy device |
| 04/24/2014 | WO2012139093A3 Selective androgen receptor modulators for treating diabetes |
| 04/24/2014 | WO2012125987A3 Delivery system |
| 04/24/2014 | WO2012122534A3 N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
| 04/24/2014 | WO2012122058A3 Alkyne substituted quinazoline compound and methods of use |
| 04/24/2014 | WO2012121939A3 Aminopyrazine compounds |
| 04/24/2014 | WO2012119078A3 COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE |
| 04/24/2014 | WO2012079020A3 Compounds that modulate store operated calcium channels |
| 04/24/2014 | WO2012078703A3 Inhibiting chromosome instability in ovarian cancer |
| 04/24/2014 | US20140113975 Biodegradable block copolymeric compositions for drug delivery |
| 04/24/2014 | US20140113973 Treatment of neural diseases or conditions |
| 04/24/2014 | US20140113972 Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status |
| 04/24/2014 | US20140113970 Dispensing system |
| 04/24/2014 | US20140113969 Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure |
| 04/24/2014 | US20140113968 Method for producing conjugated linoleic acid |
| 04/24/2014 | US20140113965 Bronchodilating beta-agonist compositions and methods |
| 04/24/2014 | US20140113964 Method of preventing and treating allergic airway diseases via intranasal gabexate mesilate |
| 04/24/2014 | US20140113962 Inhibitors of nitric oxide synthase |
| 04/24/2014 | US20140113958 HCV Combination Therapy |
| 04/24/2014 | US20140113956 Erk inhibitors for use in treating spinal muscular atrophy |
| 04/24/2014 | US20140113953 Targeting MicroRNAs for Metabolic Disorders |
| 04/24/2014 | US20140113949 Methods for reducing neurodegeneration |
| 04/24/2014 | US20140113948 Drug Combinations and Uses |
| 04/24/2014 | US20140113947 Pharmaceutical cream compositions of oxymetazoline and methods of use |
| 04/24/2014 | US20140113946 Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| 04/24/2014 | US20140113939 Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
| 04/24/2014 | US20140113936 Medicinal treatment of dermal diseases in companion animals |
| 04/24/2014 | US20140113935 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| 04/24/2014 | US20140113934 Heterocyclic compounds for treating helminth infections |
| 04/24/2014 | US20140113930 Therapeutic combination for cancer treatment |
| 04/24/2014 | US20140113929 Macrocyclic inhibitors of hepatitis c virus |
| 04/24/2014 | US20140113928 Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure and restoring glucose tolerance |
| 04/24/2014 | US20140113927 Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination |
| 04/24/2014 | US20140113926 Process for the production of an abuse-proofed solid dosage form |
| 04/24/2014 | US20140113925 Morphinan Compounds |
| 04/24/2014 | US20140113924 Novel class of non-stimulant treatment and adhd and related disorders |
| 04/24/2014 | US20140113923 Novel antiviral therapies |
| 04/24/2014 | US20140113921 Formulations of pyrimidinedione derivative compounds |
| 04/24/2014 | US20140113919 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| 04/24/2014 | US20140113918 Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer |
| 04/24/2014 | US20140113917 Pyrazole compounds as crth2 antagonists |
| 04/24/2014 | US20140113914 Pyrazine derivatives as enac blockers |
| 04/24/2014 | US20140113913 Mcl-1 as a therapeutic target in scffbw7 deficient neoplasm |
| 04/24/2014 | US20140113912 Treatment and management of cns disorders |
| 04/24/2014 | US20140113910 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 04/24/2014 | US20140113909 Combination Therapy |
| 04/24/2014 | US20140113908 [(1h-indol-5-yl) - heteroaryloxy] - (1-aza-bicyclo [3.3.1] nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders |
| 04/24/2014 | US20140113905 Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity |
| 04/24/2014 | US20140113904 Treatment of cancer with tor kinase inhibitors |
| 04/24/2014 | US20140113902 Method for obtaining 5-amino-2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine |
| 04/24/2014 | US20140113901 Imidazopyridazines as akt kinase inhibitors |
| 04/24/2014 | US20140113900 Substituted imidazopyridines and the use thereof |
| 04/24/2014 | US20140113896 Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
| 04/24/2014 | US20140113893 Highly Concentrated Stable Meloxicam Solutions for Needleless Injection |
| 04/24/2014 | US20140113892 Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| 04/24/2014 | US20140113891 Compounds that inhibit human DNA ligases and methods of treating cancer |
| 04/24/2014 | US20140113889 Treatment for dry eye |
| 04/24/2014 | US20140113888 Novel Combination of Therapeutic Agents |
| 04/24/2014 | US20140113886 Stabilized 1, 25-Dihydroxyvitamin D2 and Method of Making Same |
| 04/24/2014 | US20140113883 Therapeutic micro nutrient composition for lipolysis and sclerosis |
| 04/24/2014 | US20140113881 Antiinfective composition |
| 04/24/2014 | US20140113878 Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| 04/24/2014 | US20140113877 Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds |